Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
- Study type
- Clinical guideline
- Study name
- CPIC DPYD 2017
- Design
- Pharmacogenetic clinical guideline (2017 update)
- Source
- Clin Pharma and Therapeutics · 2017
In plain words
The drugs fluorouracil and capecitabine are used to treat several types of cancer. Some people's bodies handle these drugs differently because of differences in the DPYD gene. This guideline helps doctors interpret the result of a genetic test of this gene and, if one is available, use it to adjust the drug dose. Any change in dose should be made only on the advice of the treating doctor.
Study population
This guideline is for patients whose genotype data are already available. It applies to patients who are receiving, or are due to receive, fluoropyrimidines (5-fluorouracil and capecitabine).
Endpoints
This document is not a clinical trial and has no endpoints. Its aim is to provide information for interpreting clinical genotype tests of the DPYD (dihydropyrimidine dehydrogenase) gene so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine).
Safety and side effects
The abstract of the paper gives no data on adverse events. Details in the full text of the guideline.
Clinical significance and place in guidelines
This guideline provides a framework for interpreting DPYD genotype test results and using them in fluoropyrimidine dosing. The abstract does not give details of the dosing recommendations; for the exact dosing tables and the current status of the guideline, the full text and its updated version on the CPIC website should be consulted. Its adoption in other guidelines should also be checked separately.
Limitations
The abstract describes only the aim and scope of the guideline and does not give specific recommendations, levels of evidence or doses. The guideline considers only patients whose genotype is already available and makes no recommendations on routine screening, cost-effectiveness or detailed guidance on fluoropyrimidine use.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.